altRX vs Hims
altRX costs $50 less a month, and both sell semaglutide and tirzepatide.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hims
Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC
Visit Hims →If you are choosing between altRX and Hims, the first difference is cost: altRX is $50 a month cheaper at the entry price. Both prescribe semaglutide and tirzepatide, so moving from one to the other would not change your drug. Hims leads our six-part score, 6.8 to 6.7. Both have drawn an FDA warning letter.
altRX vs Hims price
altRX is the cheaper way in: $149 a month against $199 a month at Hims. That is $50 less each month (25% lower), or about $600 over a year of treatment.
Drug by drug: Semaglutide is cheaper at altRX ($149 a month vs $199 a month); tirzepatide is cheaper at altRX ($249 a month vs $299 a month).
Medications and formats
Both sell semaglutide and tirzepatide.
On format they match: each offers compounded injections and brand-name pens.
Where each one treats patients
altRX does not publish where it ships, and Hims lists 50 states.
Pricing
altRX
Hims
Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)
What each price covers
Both prices cover the medication itself.
altRX's price also covers the clinician visit and shipping, which Hims does not claim.
altRX is silent on lab work and coaching.
Hims is silent on shipping and lab work.
altRX
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Hims
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Where each one scores higher
Overall, Hims scores 6.8 and altRX 6.7 out of 10.
altRX is stronger on value (5.0 vs 3.0) and support (7.0 vs 3.0).
Hims is stronger on trust & safety (7.0 vs 3.5) and accessibility (10.0 vs 5.0).
Effectiveness and user experience are within half a point.
altRX
6.7/10
Hims
6.8/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent altRX a warning letter dated June 8, 2026 (letter 728236), and it is still open.
The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.
Features & Coverage
| Feature | altRX | Hims |
|---|---|---|
| Starting Price | ✓$149/mo | $199/mo |
| Features | ✓8 features | 2 features |
| States Available | Not disclosed | 50 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warning Letters | 1 letter | 1 letter |
About altRX
Compounded plans open at $149 for semaglutide and $249 for tirzepatide. Branded medication runs $1,149-$1,579, a figure that already contains the consult and the shipping. Every one of the four FDA-approved brands is stocked, Mounjaro, Ozempic, Wegovy and Zepbound, which no other entry in our directory matches. altRX works in both modalities, holds LegitScript certification, and prints the FDA compounded-medication disclaimer.
Read our full altRX review →About Hims
Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.
Read our full Hims review →Pros & Cons
altRX
What we like
- Tirzepatide costs $1249 a month, close to the $1249 median for brand-name tirzepatide across the sellers we compare
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
Watch-outs
- Semaglutide costs $1149 a month, 16% above the $990 median for brand-name semaglutide across the sellers we compare
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
- The FDA has issued altRX a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Hims
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- Names 4 pharmacies that fill its prescriptions, which most sellers do not
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
Hims wins this one, 6.8 to 6.7, above all for knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC. altRX undercuts it by $50 a month, so if the monthly bill is what decides it, altRX is the pick. altRX fits better if semaglutide from $1149/month is your priority.
Choose altRX if…
You want semaglutide from $1149/month and an opening price near $149 a month.
Choose Hims if…
You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Sesame Care
Oral orforglipron alongside the injectables
From $59/mo
Get started →Collective
Flat any-dose pricing, if you can absorb a $199 annual membership on top
From $59/mo
Get started →Found
Tirzepatide at $169/month, 37% below the typical price
From $149/mo
Get started →altRX vs Hims: FAQ
Close alternatives to altRX and Hims
- altRX vs Gala
- altRX vs Sprout Health
- altRX vs Aquivia Health
- altRX vs Vytora Health
- Hims vs Hers
- Hims vs Noom
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.